Bank of New York Mellon’s Nautilus Biotechnolgy NAUT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$229K Buy
+122,570
New +$324K ﹤0.01% 4103
2025
Q2
Sell
-102,038
Closed -$87.9K 4222
2025
Q1
$87.9K Sell
102,038
-4,659
-4% -$6.92K ﹤0.01% 4013
2024
Q4
$179K Hold
106,697
﹤0.01% 3972
2024
Q3
$304K Sell
106,697
-36,643
-26% -$94.8K ﹤0.01% 3756
2024
Q2
$335K Buy
143,340
+2,340
+2% +$6.11K ﹤0.01% 3772
2024
Q1
$415K Sell
141,000
-9,342
-6% -$26.5K ﹤0.01% 3642
2023
Q4
$450K Sell
150,342
-2,907
-2% -$8.32K ﹤0.01% 3612
2023
Q3
$484K Buy
153,249
+3,807
+3% +$12.4K ﹤0.01% 3560
2023
Q2
$578K Sell
149,442
-6,468
-4% -$18.6K ﹤0.01% 3509
2023
Q1
$432K Buy
155,910
+21,451
+16% +$45K ﹤0.01% 3558
2022
Q4
$242K Buy
134,459
+10,776
+9% +$20.8K ﹤0.01% 3891
2022
Q3
$263K Buy
123,683
+12,705
+11% +$32K ﹤0.01% 3894
2022
Q2
$298K Buy
110,978
+90,882
+452% +$338K ﹤0.01% 3880
2022
Q1
$87K Hold
20,096
﹤0.01% 4431
2021
Q4
$104K Hold
20,096
﹤0.01% 4395
2021
Q3
$123K Buy
+20,096
New +$160K ﹤0.01% 4293

Other funds holding NAUT

Bank of New York Mellon's NAUT Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Nautilus Biotechnolgy (NAUT) in Q2 2026: 122,570 shares worth $229K. The stake represents ﹤0.01% of the portfolio and ranks #4103 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in NAUT as recently as Q1 2025.

Bank of New York Mellon first reported a position in NAUT in Q3 2021 and has held it in 16 quarters since. The position peaked at $578K in Q2 2023. 38 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Bank of New York Mellon held 122,570 shares of Nautilus Biotechnolgy worth $229K as of Q2 2026.
  • Nautilus Biotechnolgy was a new Bank of New York Mellon position in Q2 2026.
  • Nautilus Biotechnolgy made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4103 holding.
  • Bank of New York Mellon first reported a position in Nautilus Biotechnolgy in Q3 2021 and has held it in 16 quarters since.
  • Bank of New York Mellon's Nautilus Biotechnolgy position peaked at $578K in Q2 2023.
  • 38 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.